Quadrivalent Recombinant Influenza Vaccine

BIOLOGICAL5 trials

Sponsors

Duke University, Sanofi Pasteur, a Sanofi Company

Conditions

Adverse Event Following ImmunisationBirth OutcomesInfluenzaInfluenza ImmunizationSafety

Phase 1

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

CompletedNCT05553301

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2022-10-03End: 2024-01-19Updated: 2025-01-24

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

CompletedNCT05650554

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2022-12-12End: 2024-04-02Updated: 2025-03-19

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

CompletedNCT06118151

Sanofi Pasteur, a Sanofi CompanyInfluenza, Influenza Immunization

Start: 2022-04-11End: 2023-02-17Updated: 2023-11-07

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

CompletedNCT06361875

Sanofi Pasteur, a Sanofi CompanyInfluenza Immunization

Start: 2024-04-01End: 2025-06-09Updated: 2025-06-19

Phase 4

Safety of RIV4 Versus IIV4 in Pregnant Women

CompletedNCT03969641

Duke UniversityAdverse Event Following Immunisation, Birth Outcomes, Safety

Start: 2019-09-05End: 2021-09-29Updated: 2023-01-11